Read by QxMD icon Read


shared collection
6 papers 100 to 500 followers
By Juvenal Jr Mottola Physician in a climical practice
D Craig Allred, Stewart J Anderson, Soonmyung Paik, D Lawrence Wickerham, Iris D Nagtegaal, Sandra M Swain, Elefetherios P Mamounas, Thomas B Julian, Charles E Geyer, Joseph P Costantino, Stephanie R Land, Norman Wolmark
PURPOSE: The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-24 study demonstrated significant benefit with adjuvant tamoxifen in patients with ductal carcinoma in situ (DCIS) after lumpectomy and radiation. Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen. PATIENTS AND METHODS: Estrogen (ER) and progesterone receptors (PgR) were evaluated in 732 patients with DCIS (41% of original study population)...
April 20, 2012: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Mike J Clarke
BACKGROUND: There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented. OBJECTIVES: In this report, the Early Breast Cancer Trialists' Collaborative Group present their third 5-yearly systematic overview (meta-analysis) of treatment with tamoxifen. SEARCH STRATEGY: Trial identification procedures for the EBCTCG overviews have been described elsewhere...
October 8, 2008: Cochrane Database of Systematic Reviews
Charlotte Lanng
About 80% of all breast cancers are oestrogen sensitive. Patients operated for breast cancer treated with tamoxifen or aromase inhibitors (AI) have a lower incidence of contralateral breast cancer. Based on this knowledge, prophylactic studies comparing tamoxifen with placebo have found a 30% reduction in breast cancer. Unacceptably many women developed endometrium cancer or thromboembolic side-effects in the tamoxifen group. Prophylactic studies have been initiated in recent years comparing AI with placebo...
September 3, 2007: Ugeskrift for Laeger
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins, M Daly, S Wieand, E Tan-Chiu, L Ford, N Wolmark
BACKGROUND: The finding of a decrease in contralateral breast cancer incidence following tamoxifen administration for adjuvant therapy led to the concept that the drug might play a role in breast cancer prevention. To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992. METHODS: Women (N=13388) at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of age with a 5-year predicted risk for breast cancer of at least 1...
September 16, 1998: Journal of the National Cancer Institute
M Baum
Tamoxifen is currently established as the endocrine treatment of choice in breast cancer. In advanced breast cancer, response rates of up to 60% in women with oestrogen receptor (ER)-positive tumours have been reported. In early breast cancer, tamoxifen can produce significant benefits, both statistically and clinically, in terms of reduction in relative risk of relapse or death in all patient subgroups (i.e. ER status, aged < or > 50 years) except premenopausal women with ER-negative tumours. The major benefit, however, is seen in women over 50 years old with ER-positive tumours...
September 1998: British Journal of Cancer
B Fisher, J Dignam, J Bryant, A DeCillis, D L Wickerham, N Wolmark, J Costantino, C Redmond, E R Fisher, D M Bowman, L DeschĂȘnes, N V Dimitrov, R G Margolese, A Robidoux, H Shibata, J Terz, A H Paterson, M I Feldman, W Farrar, J Evans, H L Lickley
BACKGROUND: In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine the effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors and no axillary lymph node involvement. The findings indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease. However, questions arose about how long the observed benefit would persist, about the duration of therapy necessary to maintain maximum benefit, and about the nature and severity of adverse effects from prolonged treatment...
November 6, 1996: Journal of the National Cancer Institute
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"